Cleared Traditional

K810875 - FECAL STAINING KIT

K810875 is an FDA 510(k) clearance for FECAL STAINING KIT, manufactured by Jayco Pharmaceuticals. The device is a Class 1 Pathology device with product code KKJ cleared through the Traditional 510(k) pathway after a 31-day FDA review.

K810875 · Jayco Pharmaceuticals · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1981
Decision
31d
Days
Class 1
Risk

K810875 is an FDA 510(k) clearance for the FECAL STAINING KIT. Classified as Sudan Iii (product code KKJ), Class I - General Controls.

Submitted by Jayco Pharmaceuticals (Mchenry, US). The FDA issued a Cleared decision on May 1, 1981 after a review of 31 days - a notably fast clearance cycle.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 864.1850 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Jayco Pharmaceuticals devices

FDA 510(k) Submission Details - K810875

510(k) Number K810875 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 31, 1981
Decision Date May 01, 1981
Days to Decision 31 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
47d faster than avg
Panel avg: 78d · This submission: 31d
Pathway characteristics
Predicate-based equivalence.

KKJ Device Classification - Class 1, General Controls

Product Code KKJ Sudan Iii
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 864.1850
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.